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Background
During recent y, a progressive emerging of tuberculosis
(T) occurred, related to the overall increased age of gen-
eral population, primary-secondary immunodeficiencies
(including frequent-prolonged exsposure to immunosup-
pressive-cytotoxic treatments), surgical and intensive
care supports, bone marrow-solid organ transplantation,
and recent immigration of people coming from T-ende-
mic areas.
Methods
Since Jan 2006, we hospitalized 78 cases of pulmonary
T, in over 75% of cases occurred in patients (p) immi-
grated from developing countries.
Results
In only 4 p resistant or multiresistant (MDR) T strains
were found, while 2 more p had a multi-resistant
(XDR) T. Although enforcing all possible measures to
increase p’adherence to treatments (empowerment, use
of i.v. formulation whenever possible, delivery of oral
drugs under direct control), over one third of p had a
very slow clinical-radiological ameliorement (2-4 mo)
(19 p of 78 even experienced an initial worsening dur-
ing early treatment), with persistence of sputum and/
or bronchoalveolar lavage (BAL) fluid positive for
Mycobacterium tuberculosis for over 2-4 mo (mean 2.3
± 0.7 mo), during apparently adequate treatment.
When excluding XDR-MDR p, which had very pro-
longed admissions (sometimes over one y), and always
deserved second-third-line drugs, in 8 more p we
observed that off-label linezolid (L) adjunct together
with at least 3 drugs with residual activity against T,
l e dt oar a p i dc l i n i c a l - r a d i ological improvement and
negative microbiological search, with consequent possi-
bility to achieve a protected discharge, supported by a
sequential, oral therapy. L was also successfully
employed in all p with XDR-MDR T, when a tempora-
rily negativization of respiratory secretions was
achieved always and only after the L adjunct to a com-
bination therapy selected on the ground of residual
in vitro susceptibility assays.
Discussion
Notwithstanding the maintained, extensive microbiologi-
cal susceptibility of M. tuberculosis strains responsible of
the great majority of cases of pulmonary T, an unex-
pected tendency of p to have a persistingly positive spu-
tum/BAL and experience prolonged hospitalization for
cure and isolation, has been recognized in the last y. No
particularly suggestive chest imaging seems predictive of
a so prolonged course, so that we presently lack of clini-
cal-radiological elements predictive of this slow treat-
ment response. The oxazolidinone L has an affordable
activity against M. tuberculosis, and an extremely ele-
vated intracellular concentration in respiratory tissues.
The increasing microbiological, pharmacological, and
clinical evidences may recommend the use as an off-
label salvage L treatment of pulmonary T refractory to
treatment, although not necessarily determined by
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© 2010 Manfredi et al; licensee BioMed Central Ltd.resistant (MDR-XDR) strains. To rely on controlled
data, randomized clinical trials including initially p with
chemioresistant T, are needed.
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